Ginkgo Bioworks (DNA) and SaponiQx, a subsidiary of Agenus (AGEN) have been awarded a 5-year contract totaling up to $31M including program options to discover and develop next-generation vaccine adjuvants, by the Defense Threat Reduction Agency’s – DTRA – Joint Science and Technology Office – JSTO – for the Chemical and Biological Defense – CBD – Program, through the Medical CBRN – Chemical, Biological, Radiological, and Nuclear – Defense Consortium – MCDC – requirement “Adjuvant Activity to Vaccines Prototype,”. Ginkgo, which is building a platform for cell programming and biosecurity, and SaponiQx, developing an adjuvant development platform, will use a combination of high-throughput empirical and artificial intelligence/machine learning approaches, including Generative Molecular Design, to develop superior novel saponin-based adjuvants. By leveraging Ginkgo’s leading platform for cell programming, the partners also intend to develop more affordable, sustainable, and scalable adjuvant manufacturing processes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Cathie Wood’s ARK Investment bought 711K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 511K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 119K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 129K shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 886K shares of Ginkgo Bioworks today